GGrantIndex
← Leaderboards

Deric L Wheeler

University Of Wisconsin-Madison

$5,593,556
Attributed
$6,723,640
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $992.7K · FY201625
$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,723,640 · 4

By mechanism

R01$3,980,325 · 2
P50$2,743,315 · 2

Top collaborators

Most similar at University Of Wisconsin-Madison

Same institution · by research overlap

Others in their field

Top investigators on “Clinic

Research focus

ClinicResponseClinical TrialsTranslatingResistanceOperative Surgical ProceduresSeriesTumorMalignant NeoplasmsIn VivoNovel TherapeuticsOverexpressionPathologistNewly DiagnosedEpidermal Growth Factor ReceptorPlayPathway InteractionsRadiationBiological ModelsMolecularCetuximabMediatingIn Vivo ModelHead And Neck Cancer

Grant awards (18)

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$604,693
R01 · FY2025 · CA · contact PI
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptors$388,023
P50 · FY2025 · CA · contact PI
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$571,864
R01 · FY2024 · CA · contact PI
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptors$368,400
P50 · FY2024 · CA · contact PI
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$579,028
R01 · FY2023 · CA · contact PI
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptors$365,499
P50 · FY2023 · CA · contact PI
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$504,584
R01 · FY2022 · CA · contact PI
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptors$374,756
P50 · FY2022 · CA · contact PI
The pathophysiological role of nuclear EGFR in TNBC$346,108
R01 · FY2020 · CA · contact PI
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy Resistance$245,644
P50 · FY2020 · DE · contact PI
The pathophysiological role of nuclear EGFR in TNBC$335,724
R01 · FY2019 · CA · contact PI
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy Resistance$249,795
P50 · FY2019 · DE · contact PI
The pathophysiological role of nuclear EGFR in TNBC$346,108
R01 · FY2018 · CA · contact PI
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy Resistance$256,986
P50 · FY2018 · DE · contact PI
The pathophysiological role of nuclear EGFR in TNBC$346,108
R01 · FY2017 · CA · contact PI
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy Resistance$247,106
P50 · FY2017 · DE · contact PI
The pathophysiological role of nuclear EGFR in TNBC$346,108
R01 · FY2016 · CA · contact PI
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy Resistance$247,106
P50 · FY2016 · DE · contact PI